Measles IgM ELISA Kit

INTENDED USE

The Measles IgM Antibody ELISA Test Kit has been designed for the detection and the quantitative determination of specific IgM antibodies against Measles in serum and plasma. Further applications in other body fluids are possible and can be requested from the Technical Service. This assay is intended for in-vitro diagnostic use only. Laboratory results can never be the only base of a medical report. The patient history and further tests have additionally to be taken into account.

GENERAL DESCRIPTION

Measles is a highly contagious viral disease characterized by a clinically distinct prodrome of fever, coryza, conjunctivitis, cough and a pathognomonic exanthem (Koplik’s spots). The disease is the result of infection with the Measles Virus, genus Morbillivirus of the family Paramyxoviridae. Ten to twelve days after infection, the most prominent and characteristic prodromal symptoms appear: coryza; a persistent barking cough; keratoconjunctivitis, often with photophobia; and fever. Generally lymphadenopathy and splenomegaly are also frequent. During this period, Koplik’s spots appear on the buccal mucosa that rapidly spread involving the entire mucous membrane. These spots are usually gone by the time the skin rash reaches its peak. The rash of Measles appears after a 3- to 5-day prodrome, some 14 days after exposure. The rash quickly becomes maculopapular and spreads rapidly over the face, neck, trunk and extremities during the next three days. At its height, the eruption has generally deepened to a reddish purple and may be associated with edema of the skin. Complications are: otitis media, pneumonia and encephalitis. Measles have a more severe expression in younger or undernourished children with a higher incidence of hemorrhage Measles, with 5% to 10% of lethal cases. In people that have been vaccinated with inactive virus (before 1968), the infection can have severe manifestations as: pneumonia, peripheral edema, pleural effusion and atypical rash. Measles are one of the most contagious infectious diseases. The virus spreads through droplets emanating from the respiratory tract of infected persons or by direct contact. The incidence of Measles has declined since the introduction of vaccination programs.

PRINCIPLE OF THE TEST

The Measles IgM antibody test kit is based on the principle of the enzyme immunoassay (EIA). Measles antigen is bound on the surface of the microtiter strips. Diluted patient serum or ready-to-use standards are pipetted into the wells of the microtiter plate. A binding between the IgM antibodies of the serum and the immobilized Measles antigen takes place. After a one hour incubation at room temperature, the plate is rinsed with diluted wash solution, in order to remove unbound material. Then ready-to-use anti-human-IgM peroxidase conjugate is added and incubated for 30 minutes. After a further washing step, the substrate (TMB) solution is pipetted and incubated for 20 minutes, inducing the development of a blue dye in the wells. The color development is terminated by the addition of a stop solution, which changes the color from blue to yellow. The resulting dye is measured spectrophotometrically at the wavelength of 450 nm. The concentration of the IgM antibodies is directly proportional to the intensity of the color.

SPECIMEN COLLECTION AND HANDLING

 Principally serum or plasma (EDTA, heparin) can be used for the determination. Serum is separated from the blood, which is aseptically drawn by venipuncture, after clotting and centrifugation. The serum or plasma samples can be stored re-frigerated (2-8°C) for up to 48 hours, for a longer storage they should be kept at -20 °C. The samples should not be frozen and thawed repeatedly. Lipotinic, hemolytic or bacterially contaminated samples can cause false positive or false negative results. For the performance of the test the samples (not the standards) have to be diluted 1:101 with ready-to-use sample diluent (e.g. 5 μL serum + 500 μL sample diluent).

REAGENTS PROVIDED

Store kit components at 2-8°C and do not use after the expiry date on the box outer label. Before use, all components should be allowed to warm up to ambient temperature (18-25°C). After use, the plate should be resealed, the bottle caps replaced and tightened and the kit stored at 2-8°C. The opened kit should be used within three months.

Mikrotiter Strips: 12 strips with 8 breakable wells each, coated with a Measles antigen (Strain Edmonston, ATCC VR-24). Ready-to-use.

Cut-Off Standard: 2 mL human serum diluted with PBS, contains a low concentration of IgM antibodies against Measles. Addition of 0.01 % methylisothiazolone and 0.01 % bromotrioxide. Ready-to-use.

Weak Positive Control: 2 mL human serum diluted with PBS, contains a medium concentration of IgM antibodies against Measles. Addition of 0.01 % methylisothiazolone and
0.01 % bromonitrodioxane. Ready-to-use.

Positive Control: 2 mL, human serum diluted with PBS, contains a high concentration of IgM antibodies against Measles. Addition of 0.01 % methylisothiazolone and 0.01 % bromonitrodioxane. Ready-to-use.

Negative Control: 2 mL, protein solution diluted with PBS, contains no IgM antibodies against Measles. Addition of 0.01 % methylisothiazolone and 0.01 % bromonitrodioxane. Ready-to-use.

Enzyme Conjugate: 15 mL, anti-human-IgM-HRP (rabbit), in protein-containing buffer solution. Addition of 0.01 % methylisothiazolone and 0.01 % bromonitrodioxane and 5 mg/L Proclin™. Ready-to-use.

Substrate: 15 mL, TMB (tetramethylbenzidine). Ready-to-use.

Stop Solution: 15 mL, 0.5 M sulfuric acid. Ready-to-use.

Sample Diluent: 60 mL, PBS/BSA buffer. Addition of 0.095 % sodium azide. Ready-to-use.

Washing Buffer: 60 mL, PBS + Tween 20, 10x concentrate. Final concentration: dilute 1+9 with distilled water. If during the cold storage crystals precipitate, the concentrate should be warmed up at 37°C for 15 minutes.

Plastic Foils: 2 pieces to cover the microtiter strips during the incubation.

Plastic Bag: Resealable, for the dry storage of non-used strips.

**MATERIALS REQUIRED BUT NOT PROVIDED**

1. 5 µL-, 100 µL-, and 500 µL micro- and multichannel pipets
2. Microtiter Plate Reader (450 nm)
3. Microtiter Plate Washer
4. Reagent tubes for the serum dilution
5. Bidistilled water

**ASSAY PROCEDURE**

1. **Reagent And Sample Preparation**

Washing Solution: dilute before use 1+9 with distilled water. If during the cold storage crystals precipitate, the concentrate should be warmed up at 37°C for 15 minutes.

1) Strict adherence to the protocol is advised for reliable performance. Any changes or modifications are the responsibility of the user.
2) All reagents and samples must be brought to room temperature before use, but should not be left at this temperature longer than necessary.
3) Standards and samples should be assayed in duplicates.
4) A standard curve should be established with each assay.
5) Return the unused microtiter strips to the plastic bag and store them dry at 2-8°C.

2. **Assay Steps**

1) Prepare a sufficient amount of microtiter wells for the standards, controls and samples in duplicate as well as for a substrate blank.
2) Pipet 100 µL each of the diluted (1:101) samples and the ready-to-use standards and controls respectively into the wells. Leave one well empty for the substrate blank.
3) Cover plate with the enclosed foil and incubate at room temperature for 60 minutes.
4) Empty the wells of the plate (dump or aspirate) and add 300 µL of diluted washing solution. This procedure is repeated totally three times. Rests of the washing buffer are afterwards removed by gentle tapping of the microtiter plate on a tissue cloth.
5) Pipet 100 µL each of ready-to-use conjugate into the wells. Leave one well empty for the substrate blank.
6) Cover plate with the enclosed foil and incubate at room temperature for 30 minutes.
7) Empty the wells of the plate (dump or aspirate) and add 300 µL of diluted washing solution. This procedure is repeated totally three times. Rests of the washing buffer are afterwards removed by gentle tapping of the microtiter plate on a tissue cloth.
8) Pipet 100 µL each of the ready-to-use substrate into the wells. This time also the substrate blank is pipetted.
9) Cover plate with the enclosed foil and incubate at room temperature for 20 minutes in the dark(e.g. drawer).
10) To terminate the substrate reaction, pipet 100 µL each of the ready-to-use stop solution into the wells. Pipet also the substrate blank.
11) After thorough mixing and wiping the bottom of the plate, perform the reading of the absorption at 450 nm (optionally reference wavelength of 620 nm). The color is stable for at least 60 minutes.

**EVALUATION**

The mean values for the measured absorptions are calculated after subtraction of the substrate blank value. The difference between the single values should not exceed 10%.

1. **Qualitative Evaluation**

The calculated absorbances for the patient sera, as mentioned above, are compared with the value for the cut-off standard. If the value of the sample is higher, there is a positive result. For a value below the cut-off standard, there is a negative result. It seems reasonable to define a range of +/-20 % around the value of the cut-off as a grey zone. In such a case the repetition of the test with the same serum or with a new sample of the same patient, taken after 2-4 weeks, is recommended. Both samples should be measured in parallel in the same run. The positive control must show at least the double absorption compared with the cut-off standard.

2. **Quantitative Evaluation**

The ready-to-use standards and controls of the Measles antibody kit are defined and expressed in arbitrary units (U/mL). This results in an exact and reproducible quantitative evaluation. Consequently for a given patient follow-up controls become possible. The values for controls and standards in units...
2. The ELISA results are printed on the labels of the vials. For a quantitative evaluation, the absorptions of the standards and controls are graphically drawn against their concentrations. From the resulting reference curve, the concentration values for each patient sample can then be extracted in relation to their absorptions. It is also possible to use automatic computer programs.

**ASSAY CHARACTERISTICS**

<table>
<thead>
<tr>
<th>Measles ELISA</th>
<th>IgG</th>
<th>IgA</th>
<th>IgM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intra-Assay-Precision</td>
<td>12.5 %</td>
<td>8.8 %</td>
<td>10.1%</td>
</tr>
<tr>
<td>Inter-Assay-Precision</td>
<td>6.9 – 15.8 %</td>
<td>4.6 – 9.1 %</td>
<td>2.8-8.7 %</td>
</tr>
<tr>
<td>Inter-Lot-Precision</td>
<td>2.7 – 12.2 %</td>
<td>2.7 – 12.2 %</td>
<td>5.5 – 13.4 %</td>
</tr>
<tr>
<td>Analytical Sensitivity</td>
<td>1.35 U/mL</td>
<td>1.15 U/mL</td>
<td>1.07 U/mL</td>
</tr>
<tr>
<td>Recovery</td>
<td>85 – 94 %</td>
<td>94 – 117 %</td>
<td>117 – 115%</td>
</tr>
<tr>
<td>Linearity</td>
<td>75 – 129 %</td>
<td>95 – 136 %</td>
<td>95 – 136 %</td>
</tr>
<tr>
<td>Clinical Sensitivity</td>
<td>100%</td>
<td>94 %</td>
<td>100%</td>
</tr>
<tr>
<td>Clinical Specificity</td>
<td>97 %</td>
<td>67 %</td>
<td>67%</td>
</tr>
</tbody>
</table>

Cross-Reactivity: No cross-reactivity to Mumps and Varicella

Interferences: No interferences to bilirubin up to 0.3 mg/mL, hemoglobin up to 8.0 mg/mL and triglycerides up to 5.0 mg/mL

**REFERENCES**